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Translational Relevance
Overall prognosis of acute myeloid leukemia (AML) remains poor. Primary refractory AML (failure to induction chemotherapy) and leukemia relapse post allogeneic stem cell transplantation (alloSCT) are among the most challenging clinical scenarios; treatment options are extremely limited. In the present study, we demonstrate that T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT), a recently identified T cell inhibitory receptor, is upregulated on CD8 + T cells from AML patients. High expression of TIGIT associates with primary refractory disease and leukemia relapse post alloSCT. Furthermore, TIGIT + CD8 + T cells exhibit features of exhaustion and show reduced capacity to produce cytokines and high susceptibility to apoptosis. Importantly their functional defects are reversed by TIGIT knockdown. This is the first study to uncover a critical role of TIGIT in leukemia pathogenesis and its significant clinical impact. Our data provide a strong rationale of targeting TIGIT for novel leukemia therapeutics.
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Author Manuscript Published OnlineFirst on January 13, 2016; DOI: 10.1158/1078-0432.CCR- Introduction Successful treatment of acute myeloid leukemia (AML) is challenging. General management involves induction chemotherapy followed by post-remission consolidation (1) . Allogeneic hematopoietic stem cell transplantation (AlloSCT) in many situations significantly improves survival. Despite considerable effort, only approximately 35% and 10% of young adult and elderly patients, respectively, are cured from their disease (2) (3) (4) . Primary refractory disease (failure to induction therapy) and leukemia relapse post alloSCT represent two major challenging scenarios that correlate with poor clinical outcomes. Novel effective leukemia therapeutics is urgently needed since treatment options are extremely limited for this patient population.
The delicate balance between immune stimulatory and inhibitory signals determines the effectiveness of anti-tumor responses (5, 6) . Recent success using reagents targeting negative regulators (so-called "immune checkpoints") offers great promise for effective cancer therapy (7) (8) (9) (10) (11) (12) . These approaches target T cell exhaustion; a unique immune inhibitory mechanism involving a state of T cell dysfunction that develops in response to persistent antigen stimulation (13) . Inhibitory pathways including programmed cell death protein 1 (PD-1), T-cell immunoglobulin domain and mucin domain 3 (TIM-3), 2B4, CD160, B-and T-lymphocyte attenuator (BTLA), and Lymphocyte-activation gene 3 (LAG-3) contribute to the development of T cell exhaustion (14) (15) (16) (17) (18) (19) (20) . Several studies including ours have demonstrated an involvement of inhibitory pathways in AML progression (21-25). Strategies for blocking immune suppression are attractive due to their relatively simple administration and the resulting increased T cell activity and enhanced tumor killing. In fact agents blocking the PD-1 pathway, nivolumab and pembrolizumab, have been recently approved by the FDA in treating several solid tumors. Early phase clinical trials testing the safety and efficacy of nivolumab in AML are currently ongoing (NCT02275533, NCT02464657, NCT02397720).
Although promising, it should be noted that single blockade of one inhibitory pathway is unlikely to accomplish an optimal anti-leukemia immune response. Leukemia may use a T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is a recently identified coinhibitory receptor that is expressed on activated T cells, Tregs, and NK cells (28-31). Similar to CTLA-4 and CD28, TIGIT shares ligands (CD155 and CD112) with its costimulatory counterpart, CD226 (32, 33) . Emerging data suggest an important inhibitory role of TIGIT in tumor immunity (34) (35) (36) . However whether TIGIT regulates anti-leukemia immune responses in patients with AML is unknown. Here we performed a phenotypic and functional study on T cells isolated from the peripheral blood of AML patients. We report that TIGIT expression is upregulated on CD8 + T cells in AML.
Importantly, a high frequency of TIGIT-expressing cells associates with primary refractory disease and leukemia relapse post alloSCT, both of which correlate with poor clinical outcome in AML. On further dissection of the immune regulatory role of TIGIT in AML, we observed that TIGIT + CD8 + T cells exhibit features of exhaustion manifested by their preferential expression on the T EMRA subset, co-expression of other inhibitory receptors, decreased capacity of producing cytokines, and high susceptibility to apoptosis. The functional defects can be reversed by knockdown of TIGIT gene expression. In addition, down regulation of CD226 likely contributes to TIGIT-mediated immune suppression. Clinical characteristics of post transplant patient cohorts were described previously (22).
Materials and Methods

Patients
Briefly samples from 11 AML patients who received alloSCT from 2013 to 2015 were selected, five of whom had leukemia relapse at 2-6 months post transplantation; the other 6 patients remained in remission at the time of blood collection (3-6 months). Age and gender were evenly distributed in relapse vs. remission patients. Most patients received 8/8
HLA-matched transplantations from filgrastim-mobilized peripheral blood stem cells. One patient received 7/8 matched donor cells. One patient received bone marrow-derived stem cells. Seven patients (3 from each relapse, 4 from remission group) underwent ablative conditioning, the other 4 patients (two from each group) received non-ablative conditioning regimens due to age or co-morbidity.
Immunofluorescence staining and flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) were incubated with directly conjugated mAbs for 30 minutes at 4°C. The cells were then washed before flow cytometric analysis. mAbs used were anti-human CD3-PerCp-Cy5.5 or CD3-BV421, CD4-FITC or CD4-V500, CD8-APC-H7, CD45RA-PE-Cy7, CCR7-PerCp-Cy5.5, CD95-FITC (BD Biosciences, San Diego, CA, USA), PD-1-PE, CD226-FITC, BTLA-BV421, CD160-PE-Cy7 (BioLegend, San Diego, CA, USA), TIGIT-APC (Ebioscience, San Diego, CA, USA), LAG-3-AF700 (R&D Systems, Minneapolis, MN, USA) antibodies, and corresponding isotype controls. Data acquisition was performed on a LSR Fortessa flow cytometer (BD Biosciences) and data analysis was performed using FlowJo Software (Tree Star, Ashland, OR, USA).
In vitro stimulation and intracellular staining
PBMCs were cultured in RPMI-1640 medium (GIBCO, Grand Island, NY, USA) containing 10% FBS and stimulated with anti-CD3/CD28 (2 µg/mL and 5 µg/mL, Ebioscience) or 
Apoptosis analysis
Apoptosis rates were measured using PE Annexin V Apoptosis Detection Kit (BD Biosciences) following the manufacturer's instructions, in combination with markers for T cells. Samples were analyzed by flow cytometry.
Cell separation, culture
CD8
+ T cells were isolated from PBMCs using positive selection with EasySep™ Human 
CFSE staining and T cell proliferation assay
Statistical analysis
Data are expressed as the mean ± standard deviation (SD). GraphPad5 (GraphPad Software, La Jolla, CA, USA) or SPSS (IBM Corporation, New York, NY, USA) were used for statistical calculations. The normality of each variable was evaluated using the Kolmogorov-Smirnov test. In cases of normally distributed data, the comparison of variables was performed using unpaired or paired where specified) 2-tailed Student's t-tests for unpaired and paired data, respectively. When the data were not normally distributed, the comparison of variables was performed with a Mann-Whitney U test or a Wilcoxon matched-pairs signed rank test for unpaired and paired data, respectively. Comparisons of patient characteristics were analyzed using Fisher's exact test (categorical variables) or Willcoxon-rank sum test (continuous variables). To evaluate correlation, Pearson's correlation coefficients were used. For all analyses, P-values less than 0.05 were considered statistically significant.
Results
TIGIT is elevated on CD8 + T cells in patients with AML
To determine whether TIGIT is involved in the pathogenesis of AML, we assessed PBMCs from 25 AML patients at initial diagnosis for TIGIT expression on both CD4 + and CD8 + T cells. PBMCs from 18 healthy donors (HD) were tested as controls. As shown in Figure 1A -B, the frequency of TIGIT + cells among CD8 + T cells from AML patients was significantly higher than those from HD (mean frequency 47.4%±19.9% vs. 32.9%±12.9%, P=0.0101).
In contrast, expression of TIGIT on CD4 + T cells was comparable between AML patients and HD. We further evaluated expression of TIGIT ligands, CD155 and CD112, on leukemia cells features. Blast percentage and absolute counts in peripheral blood tended to be higher in patients who express high TIGIT, but did not reach statistical significance (table1). No difference was detected in blast percentage of bone marrow. We next investigated whether the level of TIGIT is associated with failure to achieve complete remission (CR) after induction chemotherapy, which is defined as primary refractory disease in AML (37) . Three patients died of induction related complications before we were able to assess CR and one patient went to hospice without induction treatment due to multiple co-morbidities and poor performance. Among the 21 AML patients of whom the induction response was able to be evaluated, we found a significantly higher rate of primary refractory disease in the high-TIGIT group compared with the low-TIGIT group (5/8 (62.5%) vs. 1/13 (7.7%),
P=0.014, table 1
). These data demonstrate an association of TIGIT expression on CD8 + T cells with primary refractory disease in AML.
Elevated TIGIT expression on CD8 + T cells post alloSCT associates with AML relapse
Leukemia relapse post alloSCT is another challenging clinical scenario in AML management.
Research. Figure 2A ). CD4 + T cells showed a similar trend but did not achieve statistical significance (P =0.1660; Figure 2B ). Thus TIGIT expression on CD8 + T cells associates with leukemia relapse post alloSCT.
Collectively these results demonstrate a strong correlation of TIGIT expression on CD8 + T cells in patients with refractory AML and post-alloSCT progression, suggesting that TIGIT may play a critical role in the pathogenesis of AML. Figure 2A) . Consistently, TIGIT + CD8 + T cells showed an increased proliferation index in the CFSE assay (Supplemental Figure 2B) . Additionally, perforin staining was elevated on TIGIT + CD8 + T cells (Supplementary Figure 2C) , indicating a stronger killing potential. Thus TIGIT + CD8 + T cells are functional impaired to some degree by displaying low capacity of cytokine production and high susceptibility to apoptosis, but retaining their capacity for proliferation and potential to kill.
To better understand the contribution of TIGIT in inhibition of CD8 + T cell function in AML patients, we used a specific siRNA to knock down TIGIT expression in CD8 + T cells from AML patients ( Figure 4C ). Intracellular cytokine staining assays were performed on CD8 + T cells that had TIGIT knocked down. We observed a significant increase of TNF-α and IFN-γ production after TIGIT knockdown ( Figure 4D ). Consistently CD8 + T cells were less susceptible to apoptosis upon TIGIT knockdown manifested by decreased expression of Annexin V after siRNA transfection ( Figure 4E ). These data demonstrate a pivotal role for TIGIT in inhibition of cytokine release and induction of apoptosis, thus suppressing T cell function in AML patients.
CD226 is down-regulated on CD8 + T cells in AML patients
Recent studies suggest that TIGIT can exert inhibitory regulation by competing with its AML. In contrast to the up-regulation of TIGIT, CD226 was significantly decreased in AML patients compared to that of HD (68.2%±8.2% vs. 77.5%±13.6%, P=0.0492, Figure 5A- while retaining others at an early stage (13, (41) (42) (43) . In fact, it has been reported that T cells from chronic lymphocytic leukemia (CLL) patients exhibit an exhausted defect in proliferation and cytotoxicity, but retain the capacity for cytokine production (27). In our study, TIGIT + CD8 + T cells from AML patients lost the capacity for cytokine production, but retained the capacity for proliferation and cytotoxicity. Third, TIGIT + CD8 + T cells tested in our study are polyclonal, which could contribute to the heterogeneity of the results. Our finding that high expression of TIGIT associates with primary refractory disease and leukemia relapse post transplantation in AML patients has significant clinical implications.
Primary refractory disease, defined as failure to achieving CR after 1 to 2 cycles of intense induction therapy, accounts for 10% to 40% of AML patients (37, 46) . This represents one of the most challenging clinical scenarios in management of AML and is not typically curable by conventional salvage therapy. AlloSCT offers a higher cure rate. However, this high-risk procedure is often not feasible due to high age, co-morbidity, poor performance status, and severe complications of induction treatment. How to optimize the initial therapy and prevent primary refractory disease is currently an active research area. It is crucial to identify the patient population with high risk. Our study reveals an association of high-TIGIT at initial diagnosis with primary refractory disease, suggesting that testing TIGIT might be a feasible approach for early risk stratification. Most importantly this finding provides a strong rationale for early intervention in that combining induction chemotherapy with agents blocking TIGIT might be the key to improve clinical outcome.
AlloSCT is in many situations the only curative measure for AML. For patients who are fit
Research. and able to receive this procedure, alloSCT significantly increases survival. However leukemia relapse does occur after transplantation. According to the data from CIBMTR, disease relapse is the top cause of death, accounting for ~40% of post-transplant deaths (47) .
Once leukemia relapse occurs, the prognosis is generally poor. Currently there is no effective treatment available for this patient population. Identification of novel therapeutic targets is critical to develop effective treatments and improve clinic outcomes. Eradication of leukemia in alloSCT largely relies on graft versus leukemia (GVL) mediated by donor T cells (48, 49) .
Leukemia relapse is considered a failure of GVL. Our finding that high TIGIT expression on
CD8
+ T cells associates with leukemia relapse post transplantation suggests that negative regulation by TIGIT on donor T cells might contribute to GVL failure and leukemia relapse, making a case for targeting TIGIT for effective treatment of leukemia relapse post transplantation.
In summary, our study demonstrates that TIGIT is an important negative immune regulator in AML, making it an attractive therapeutic target for effective leukemia control. Each square represents data from one patient. P values were obtained by unpaired t test.
*P<0.05 
